AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	719	23593-75-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clotrimazole lotrimin rimazole locasten	An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Molecular weight: 344.84 Formula: C22H17ClN2 CLOGP: 5 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 17.82 ALOGS: -5.37 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clotrimazole
lotrimin
rimazole
locasten

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Molecular weight: 344.84
Formula: C22H17ClN2
CLOGP: 5
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 17.82
ALOGS: -5.37
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	V

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.03 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	5.156		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	4.207		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	5.188	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	17.498	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	0.060	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	0.260	%	High	1
herg	hERG pIC50	5.566	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	32.885	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	63.680	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	0.080	%	High	1
kinase-selectivity-class	ACVR2A,AXL,ERBB2,GRK2,MAP2K6,PDK4,SIK2,SIK3	8
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIK3CB,PRKDC	19
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	12.331		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	63.533		High	1
mppb	Mouse plasma protein binding (% unbound)	0.150		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	14.355		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		High	1
pppb	Pig plasma protein binding (% unbound)	0.260	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	73.961	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	0.270	%	High	1
rppb	Rat plasma protein binding (% unbound)	0.180	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	1.734	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Feb. 3, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	1168.45	13.34	420	23157	37550	90567320
Schizoaffective disorder	704.21	13.34	180	23397	4967	90599903
Drug level increased	435.93	13.34	189	23388	27573	90577297
Chronic sinusitis	430.00	13.34	179	23398	23623	90581247
Paraesthesia oral	350.40	13.34	169	23408	31490	90573380
Vaginal flatulence	344.33	13.34	128	23449	12510	90592360
Oral candidiasis	326.42	13.34	167	23410	35288	90569582
Female genital tract fistula	324.79	13.34	135	23442	17733	90587137
Proctitis	320.89	13.34	128	23449	15131	90589739
Radiculopathy	316.89	13.34	134	23443	18371	90586499
Vaginal discharge	300.56	13.34	131	23446	19333	90585537
Electrocardiogram QT prolonged	291.92	13.34	200	23377	72256	90532614
Procedural pain	286.57	13.34	150	23427	33210	90571660
Haematochezia	204.51	13.34	160	23417	70753	90534117
Rectal haemorrhage	203.31	13.34	170	23407	82574	90522296
Colitis	187.10	13.34	151	23426	69791	90535079
Frequent bowel movements	171.84	13.34	132	23445	56803	90548067
Colitis ulcerative	171.64	13.34	135	23442	60131	90544739
Sinus rhythm	134.74	13.34	37	23540	1349	90603521
Swollen tongue	128.79	13.34	102	23475	45854	90559016
Dyspepsia	119.11	13.34	197	23380	197963	90406907
Drug interaction	111.01	13.34	231	23346	276222	90328648
Erythema	108.20	13.34	205	23372	229041	90375829
Therapeutic product effect incomplete	106.24	13.34	185	23392	193711	90411159
Swelling face	94.29	13.34	111	23466	81241	90523629
Persistent genital arousal disorder	88.48	13.34	23	23554	677	90604193
Drug ineffective	81.20	13.34	625	22952	1383673	89221197
Weight decreased	79.47	13.34	248	23329	379662	90225208
Pemphigus	72.14	13.34	3	23574	326861	90278009
Constipation	71.99	13.34	197	23380	280198	90324672
Systemic lupus erythematosus	71.79	13.34	6	23571	361890	90242980
Headache	62.22	13.34	410	23167	862336	89742534
Angioedema	59.89	13.34	79	23498	64797	90540073
Vulvovaginal candidiasis	59.36	13.34	26	23551	3874	90600996
Toxic shock syndrome	57.77	13.34	18	23559	1026	90603844
Wound complication	57.45	13.34	27	23550	4736	90600134
Endocrine ophthalmopathy	57.27	13.34	18	23559	1056	90603814
Therapeutic product effect decreased	53.96	13.34	5	23572	277566	90327304
Hand deformity	53.41	13.34	7	23570	296355	90308515
Dysphonia	50.94	13.34	72	23505	63012	90541858
Abdominal pain	48.79	13.34	218	23359	395503	90209367
Anaemia	48.60	13.34	201	23376	352601	90252269
Candida infection	47.16	13.34	51	23526	34006	90570864
Glossodynia	46.61	13.34	13	23564	321766	90283104
Swelling of eyelid	45.31	13.34	24	23553	5430	90599440
Eyelid disorder	44.63	13.34	18	23559	2185	90602685
Nasal ulcer	44.60	13.34	19	23558	2647	90602223
Wound	44.33	13.34	12	23565	302968	90301902
Malaise	42.42	13.34	279	23298	585707	90019163
Rheumatoid arthritis	41.90	13.34	21	23556	362593	90242277
Nausea	41.19	13.34	455	23122	1109861	89495009
Mean cell haemoglobin increased	40.62	13.34	20	23557	3885	90600985
Helicobacter infection	39.36	13.34	6	23571	226844	90378026
Hepatic enzyme increased	38.61	13.34	23	23554	360713	90244157
Vanishing bile duct syndrome	37.73	13.34	14	23563	1358	90603512
Irritable bowel syndrome	37.12	13.34	5	23572	207443	90397427
Eye infection toxoplasmal	35.23	13.34	10	23567	412	90604458
Pyrexia	34.98	13.34	292	23285	660193	89944677
Impaired healing	34.77	13.34	9	23568	234190	90370680
Arthropathy	34.33	13.34	27	23550	366215	90238655
Disturbance in sexual arousal	34.05	13.34	9	23568	283	90604587
Vitritis infective	33.88	13.34	6	23571	24	90604846
Abdominal discomfort	33.63	13.34	45	23532	477283	90127587
Toxicity to various agents	32.75	13.34	17	23560	287829	90317041
Synovitis	32.59	13.34	23	23554	329729	90275141
Alopecia	32.58	13.34	49	23528	495022	90109848
Perineal pain	32.04	13.34	10	23567	573	90604297
Folliculitis	30.05	13.34	8	23569	204345	90400525
Discomfort	30.04	13.34	17	23560	274318	90330552
Fibromyalgia	28.63	13.34	9	23568	206260	90398610
Pelvic pain	28.60	13.34	27	23550	15330	90589540
Liver injury	28.49	13.34	5	23572	170562	90434308
Febrile neutropenia	28.20	13.34	98	23479	158251	90446619
General physical health deterioration	27.61	13.34	31	23546	355084	90249786
Musculoskeletal stiffness	27.61	13.34	22	23555	296510	90308360
Purpura senile	27.43	13.34	9	23568	606	90604264
Dyslipidaemia	27.37	13.34	22	23555	10085	90594785
Female reproductive tract disorder	27.13	13.34	9	23568	627	90604243
Mobility decreased	26.80	13.34	16	23561	250718	90354152
Urogenital infection fungal	26.41	13.34	5	23572	31	90604839
Genital pain	25.59	13.34	9	23568	749	90604121
Inflammation	24.42	13.34	8	23569	178584	90426286
Vitamin D decreased	24.12	13.34	22	23555	11957	90592913
Tarsal tunnel syndrome	23.96	13.34	8	23569	569	90604301
Lung disorder	23.75	13.34	5	23572	149878	90454992
Tongue blistering	23.46	13.34	11	23566	1919	90602951
Nasopharyngitis	23.34	13.34	44	23533	407060	90197810
Sleep disorder due to general medical condition, insomnia type	23.26	13.34	3	23574	128691	90476179
Eye infection	22.69	13.34	23	23554	14231	90590639
Synovial cyst	22.53	13.34	21	23556	11731	90593139
Vulvovaginal inflammation	22.34	13.34	9	23568	1089	90603781
Feeding disorder	22.13	13.34	25	23552	17487	90587383
Drug ineffective for unapproved indication	21.39	13.34	51	23526	66593	90538277
Subcutaneous abscess	21.29	13.34	16	23561	6650	90598220
Drug hypersensitivity	20.97	13.34	57	23520	463552	90141318
Post viral fatigue syndrome	20.91	13.34	6	23571	257	90604613
Lymphadenitis	20.47	13.34	13	23564	4124	90600746
Type 2 diabetes mellitus	20.30	13.34	14	23563	203230	90401640
Vulvovaginal discomfort	19.98	13.34	11	23566	2686	90602184
Skin laceration	19.96	13.34	29	23548	26006	90578864
Vulvovaginal pain	19.94	13.34	12	23565	3462	90601408
Congenital absence of bile ducts	19.92	13.34	4	23573	35	90604835
Pain	19.73	13.34	366	23211	995975	89608895
Swelling	18.59	13.34	52	23525	419006	90185864
Treatment failure	18.17	13.34	32	23545	303896	90300974
Resorption bone increased	18.14	13.34	8	23569	1211	90603659
Angiodermatitis	18.01	13.34	5	23572	190	90604680
Intentional product use issue	17.89	13.34	18	23559	216874	90387996
Reperfusion arrhythmia	17.00	13.34	5	23572	234	90604636
Mouth ulceration	16.69	13.34	34	23543	39940	90564930
Conjunctivitis	16.61	13.34	27	23550	26679	90578191
Neutropenic sepsis	16.60	13.34	22	23555	18108	90586762
Sexual dysfunction	16.40	13.34	12	23565	4792	90600078
Vestibular disorder	16.31	13.34	8	23569	1541	90603329
Hypoaesthesia	16.27	13.34	36	23541	314174	90290696
Urinary tract infection	16.04	13.34	135	23442	305497	90299373
Cardiac infection	16.02	13.34	6	23571	597	90604273
Psoriatic arthropathy	15.58	13.34	22	23555	228313	90376557
Skin bacterial infection	15.58	13.34	6	23571	645	90604225
Freezing phenomenon	15.13	13.34	8	23569	1804	90603066
Hypertension	14.77	13.34	65	23512	457467	90147403
Flatulence	14.75	13.34	33	23544	41334	90563536
Bursitis	14.63	13.34	8	23569	131646	90473224
Sleep disorder	14.61	13.34	18	23559	198012	90406858
Therapeutic product effect delayed	14.52	13.34	10	23567	3631	90601239
Congenital uterine anomaly	14.30	13.34	4	23573	156	90604714
Overdose	14.29	13.34	12	23565	157697	90447173
Wheezing	14.29	13.34	25	23552	238055	90366815
Sinusitis	14.18	13.34	44	23533	343044	90261826
Intentional product misuse	14.17	13.34	3	23574	89601	90515269
Arthralgia	14.13	13.34	132	23445	778390	89826480
Liver disorder	14.02	13.34	7	23570	121262	90483608
Arthrodesis	13.76	13.34	9	23568	3003	90601867
Aplastic anaemia	13.56	13.34	17	23560	13252	90591618

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary vasculitis	355.43	15.84	112	11859	6154	42603210
Neuritis	339.64	15.84	108	11863	6112	42603252
Neurological symptom	296.84	15.84	110	11861	9881	42599483
Eosinophilic granulomatosis with polyangiitis	293.47	15.84	105	11866	8533	42600831
Respiratory symptom	267.77	15.84	105	11866	11001	42598363
Pulmonary alveolar haemorrhage	264.73	15.84	113	11858	14703	42594661
Total lung capacity abnormal	241.91	15.84	77	11894	4366	42604998
Vasculitis	228.98	15.84	109	11862	18285	42591079
Pseudoaneurysm infection	227.05	15.84	41	11930	171	42609193
Vascular pseudoaneurysm ruptured	216.41	15.84	45	11926	438	42608926
Mite allergy	212.44	15.84	72	11899	4974	42604390
Mycotic allergy	210.68	15.84	71	11900	4820	42604544
Sleep disorder due to a general medical condition	209.86	15.84	101	11870	17352	42592012
Dust allergy	208.55	15.84	72	11899	5260	42604104
Forced expiratory volume decreased	208.36	15.84	79	11892	7551	42601813
Conjunctivitis allergic	205.07	15.84	73	11898	5838	42603526
Pulmonary fibrosis	204.29	15.84	114	11857	26567	42582797
Spirometry abnormal	203.25	15.84	70	11901	5076	42604288
Obstructive airways disorder	195.61	15.84	108	11863	24651	42584713
Hypothyroidism	187.32	15.84	115	11856	31969	42577395
Antineutrophil cytoplasmic antibody positive	186.57	15.84	63	11908	4302	42605062
Normochromic normocytic anaemia	178.37	15.84	74	11897	8957	42600407
Full blood count abnormal	169.09	15.84	105	11866	29771	42579593
Haemoptysis	164.94	15.84	122	11849	46045	42563319
Nodule	152.05	15.84	73	11898	12461	42596903
Arteriosclerosis coronary artery	146.19	15.84	81	11890	18596	42590768
Wheezing	140.27	15.84	119	11852	54662	42554702
Asthma	138.74	15.84	125	11846	62189	42547175
Lung disorder	134.93	15.84	110	11861	47813	42561551
Arteriosclerosis	129.88	15.84	74	11897	17915	42591449
Loss of personal independence in daily activities	129.13	15.84	109	11862	49707	42559657
Therapeutic product effect incomplete	115.81	15.84	120	11851	70819	42538545
Capillaritis	110.56	15.84	36	11935	2192	42607172
Candida infection	104.96	15.84	69	11902	21541	42587823
Arterial haemorrhage	95.46	15.84	28	11943	1201	42608163
Anxiety	93.39	15.84	139	11832	118421	42490943
Productive cough	85.49	15.84	88	11883	51479	42557885
Hypoxia	79.58	15.84	98	11873	69688	42539676
Shock haemorrhagic	62.63	15.84	45	11926	16197	42593167
Thrombosis	57.74	15.84	83	11888	68428	42540936
Pain in extremity	53.03	15.84	125	11846	150479	42458885
Graft ischaemia	49.93	15.84	9	11962	37	42609327
Retroperitoneal abscess	45.39	15.84	12	11959	349	42609015
Pulmonary embolism	43.96	15.84	101	11870	119511	42489853
Dyspnoea	37.55	15.84	232	11739	442389	42166975
Off label use	29.02	15.84	88	11883	638247	41971117
Toxicity to various agents	26.19	15.84	16	11955	229120	42380244
Sleep disorder	25.16	15.84	47	11924	48048	42561316
Keratitis bacterial	24.65	15.84	6	11965	124	42609240
Infective aneurysm	21.99	15.84	9	11962	1050	42608314
Drug ineffective	21.93	15.84	97	11874	630100	41979264
Condition aggravated	21.58	15.84	136	11835	260618	42348746
Abdominal abscess	19.37	15.84	14	11957	5079	42604285
Temperature regulation disorder	17.94	15.84	8	11963	1151	42608213
Retroperitoneal haematoma	17.94	15.84	11	11960	3040	42606324
Skin infection	17.34	15.84	17	11954	9363	42600001
Lip haemorrhage	16.35	15.84	7	11964	913	42608451
Psoriasis area severity index increased	16.28	15.84	4	11967	86	42609278
Hypoglycaemia neonatal	15.92	15.84	9	11962	2141	42607223

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	417.06	14.07	173	30088	21486	110537552
Chronic sinusitis	402.32	14.07	176	30085	24908	110534130
Pulmonary vasculitis	357.09	14.07	113	30148	6447	110552591
Vaginal flatulence	339.28	14.07	127	30134	12017	110547021
Neuritis	327.68	14.07	109	30152	7290	110551748
Female genital tract fistula	324.96	14.07	134	30127	16385	110542653
Paraesthesia oral	320.69	14.07	165	30096	33506	110525532
Radiculopathy	304.63	14.07	134	30127	19202	110539836
Vaginal discharge	301.33	14.07	130	30131	17778	110541260
Proctitis	298.41	14.07	127	30134	16800	110542238
Oral candidiasis	289.84	14.07	170	30091	44590	110514448
Eosinophilic granulomatosis with polyangiitis	277.69	14.07	106	30155	10580	110548458
Procedural pain	264.88	14.07	148	30113	35417	110523621
Neurological symptom	255.07	14.07	111	30150	15497	110543541
Total lung capacity abnormal	245.52	14.07	78	30183	4505	110554533
Respiratory symptom	243.29	14.07	106	30155	14839	110544199
Pulmonary alveolar haemorrhage	243.09	14.07	116	30145	20034	110539004
Therapeutic product effect incomplete	230.94	14.07	295	29966	223510	110335528
Pseudoaneurysm infection	227.31	14.07	41	30220	175	110558863
Vascular pseudoaneurysm ruptured	209.63	14.07	45	30216	531	110558507
Dust allergy	209.53	14.07	74	30187	5927	110553111
Mite allergy	208.12	14.07	73	30188	5730	110553308
Mycotic allergy	206.29	14.07	73	30188	5881	110553157
Spirometry abnormal	204.25	14.07	71	30190	5426	110553612
Conjunctivitis allergic	202.79	14.07	75	30186	6856	110552182
Vasculitis	190.43	14.07	120	30141	35753	110523285
Antineutrophil cytoplasmic antibody positive	182.59	14.07	64	30197	5012	110554026
Forced expiratory volume decreased	174.78	14.07	81	30180	13095	110545943
Haematochezia	161.60	14.07	178	30083	115346	110443692
Normochromic normocytic anaemia	160.02	14.07	76	30185	12981	110546057
Arteriosclerosis coronary artery	153.66	14.07	92	30169	25026	110534012
Rectal haemorrhage	147.84	14.07	173	30088	119660	110439378
Obstructive airways disorder	147.43	14.07	113	30148	46036	110513002
Frequent bowel movements	143.79	14.07	134	30127	71256	110487782
Colitis ulcerative	134.65	14.07	134	30127	77229	110481809
Candida infection	130.71	14.07	107	30154	47902	110511136
Colitis	128.34	14.07	149	30112	102174	110456864
Haemoptysis	123.08	14.07	123	30138	71231	110487807
Sleep disorder due to a general medical condition	117.04	14.07	104	30157	52008	110507030
Dyspepsia	117.04	14.07	197	30064	190768	110368270
Full blood count abnormal	116.33	14.07	107	30154	55945	110503093
Hypothyroidism	115.44	14.07	120	30141	72779	110486259
Arteriosclerosis	114.56	14.07	76	30185	24691	110534347
Swollen tongue	113.34	14.07	109	30152	60253	110498785
Capillaritis	108.25	14.07	36	30225	2403	110556635
Nodule	95.75	14.07	76	30185	32555	110526483
Pulmonary fibrosis	85.97	14.07	122	30139	101920	110457118
Swelling face	83.18	14.07	114	30147	92207	110466831
Persistent genital arousal disorder	78.57	14.07	21	30240	655	110558383
Erythema	76.30	14.07	213	30048	291234	110267804
Arterial haemorrhage	65.13	14.07	28	30233	3791	110555247
Vulvovaginal candidiasis	62.39	14.07	26	30235	3259	110555779
Hypoxia	57.10	14.07	116	30145	129399	110429639
Weight decreased	54.62	14.07	263	29998	467794	110091244
Shock haemorrhagic	54.55	14.07	51	30210	27196	110531842
Toxicity to various agents	54.44	14.07	32	30229	480523	110078515
Toxic shock syndrome	54.03	14.07	19	30242	1501	110557537
Endocrine ophthalmopathy	52.03	14.07	18	30243	1355	110557683
Therapeutic product effect decreased	51.65	14.07	4	30257	244312	110314726
Systemic lupus erythematosus	51.50	14.07	5	30256	254333	110304705
Constipation	51.48	14.07	214	30047	357572	110201466
Productive cough	51.12	14.07	103	30158	114202	110444836
Headache	50.09	14.07	412	29849	881965	109677073
Loss of personal independence in daily activities	49.88	14.07	120	30141	149900	110409138
Cleft palate	48.71	14.07	13	30248	403	110558635
Thrombosis	45.16	14.07	95	30166	108567	110450471
Swelling of eyelid	44.96	14.07	26	30235	6627	110552411
Nasal ulcer	44.22	14.07	19	30242	2568	110556470
Asthma	43.54	14.07	159	30102	250132	110308906
Rheumatoid arthritis	43.32	14.07	14	30247	299599	110259439
Angioedema	43.14	14.07	88	30173	98412	110460626
Eyelid disorder	42.22	14.07	18	30243	2387	110556651
Dysphonia	42.10	14.07	75	30186	75854	110483184
Graft ischaemia	39.56	14.07	9	30252	141	110558897
Retroperitoneal abscess	39.55	14.07	12	30249	594	110558444
Impaired healing	39.47	14.07	4	30257	196713	110362325
Overdose	39.39	14.07	8	30253	233786	110325252
Anxiety	37.43	14.07	190	30071	344888	110214150
Hepatic enzyme increased	36.84	14.07	21	30240	320871	110238167
Glossodynia	36.58	14.07	8	30253	221996	110337042
Mean cell haemoglobin increased	35.45	14.07	21	30240	5596	110553442
Abdominal pain	34.86	14.07	250	30011	512739	110046299
Folliculitis	34.72	14.07	3	30258	167650	110391388
Irritable bowel syndrome	33.84	14.07	3	30258	164212	110394826
Wound	32.08	14.07	12	30249	234425	110324613
Lung disorder	30.98	14.07	114	30147	179933	110379105
Fibromyalgia	30.62	14.07	5	30256	170904	110388134
Pelvic pain	30.31	14.07	29	30232	15913	110543125
Vitritis infective	30.05	14.07	6	30255	48	110558990
Synovitis	29.97	14.07	19	30242	274073	110284965
Musculoskeletal stiffness	29.77	14.07	20	30241	279802	110279236
Eye infection toxoplasmal	28.94	14.07	10	30251	750	110558288
Wheezing	28.69	14.07	142	30119	255088	110303950
Wound complication	28.67	14.07	19	30242	6158	110552880
Pulmonary embolism	28.27	14.07	125	30136	214349	110344689
Inflammation	27.97	14.07	9	30252	193229	110365809
Liver injury	27.86	14.07	4	30257	150409	110408629
Intentional product use issue	27.35	14.07	17	30244	247889	110311149
Alopecia	27.17	14.07	36	30225	364717	110194321
Anaemia	27.05	14.07	248	30013	546838	110012200
Clostridium difficile colitis	26.55	14.07	45	30216	43733	110515305
Vanishing bile duct syndrome	25.82	14.07	14	30247	3154	110555884
Intentional overdose	25.80	14.07	3	30258	132498	110426540
Aplastic anaemia	24.93	14.07	32	30229	24276	110534762
Malaise	24.41	14.07	286	29975	671533	109887505
Tarsal tunnel syndrome	23.95	14.07	8	30253	541	110558497
Arthropathy	23.93	14.07	26	30235	287496	110271542
Liver disorder	23.68	14.07	5	30256	142238	110416800
Urogenital infection fungal	23.53	14.07	5	30256	56	110558982
Eye infection	23.15	14.07	24	30237	14494	110544544
Purpura senile	23.06	14.07	8	30253	607	110558431
Dyslipidaemia	22.99	14.07	25	30236	15940	110543098
Tongue blistering	22.89	14.07	11	30250	1926	110557112
Nausea	22.86	14.07	469	29792	1235221	109323817
Synovial cyst	22.12	14.07	21	30240	11409	110547629
Disturbance in sexual arousal	22.12	14.07	7	30254	399	110558639
Vulvovaginal pain	21.45	14.07	12	30249	2872	110556166
Drug hypersensitivity	21.38	14.07	59	30202	454031	110105007
Keratitis bacterial	21.13	14.07	6	30255	235	110558803
Nasopharyngitis	21.09	14.07	48	30213	394313	110164725
Abdominal discomfort	21.01	14.07	48	30213	393810	110165228
General physical health deterioration	20.98	14.07	54	30207	425241	110133797
Vitamin D decreased	20.94	14.07	21	30240	12194	110546844
Bursitis	20.76	14.07	5	30256	129913	110429125
Female reproductive tract disorder	20.66	14.07	7	30254	495	110558543
Post viral fatigue syndrome	20.12	14.07	6	30255	280	110558758
Product use issue	20.06	14.07	34	30227	311661	110247377
Genital pain	19.80	14.07	9	30252	1391	110557647
Type 2 diabetes mellitus	19.76	14.07	12	30249	177220	110381818
Intentional product misuse	19.57	14.07	6	30255	132898	110426140
Infective aneurysm	19.25	14.07	9	30252	1483	110557555
Gingival swelling	19.12	14.07	14	30247	5316	110553722
Vulvovaginal discomfort	19.04	14.07	10	30251	2114	110556924
Pain	18.47	14.07	365	29896	954590	109604448
Discomfort	18.33	14.07	19	30242	214688	110344350
Sinusitis	17.63	14.07	34	30227	296654	110262384
Angiodermatitis	17.61	14.07	5	30256	196	110558842
Memory impairment	17.30	14.07	17	30244	196927	110362111
Skin exfoliation	17.22	14.07	58	30203	87593	110471445
Infusion related reaction	16.93	14.07	169	30092	380993	110178045
Abdominal abscess	16.68	14.07	16	30245	8803	110550235
Pain in extremity	16.62	14.07	205	30056	486913	110072125
Pyrexia	16.58	14.07	341	29920	897924	109661114
Flatulence	16.55	14.07	41	30220	52108	110506930
Myelosuppression	16.37	14.07	3	30258	94337	110464701
Psoriatic arthropathy	16.14	14.07	18	30243	196743	110362295
Urinary tract infection	16.14	14.07	148	30113	326134	110232904
Mobility decreased	16.12	14.07	25	30236	237397	110321641
Resorption bone increased	16.00	14.07	8	30253	1526	110557512
Perineal pain	15.95	14.07	8	30253	1537	110557501
Schizoaffective disorder	15.42	14.07	10	30251	3126	110555912
Reperfusion arrhythmia	15.41	14.07	5	30256	309	110558729
Rash pruritic	15.13	14.07	60	30201	98009	110461029
Cardiac infection	15.07	14.07	6	30255	669	110558369
Dyspnoea	14.86	14.07	402	29859	1106470	109452568
Febrile neutropenia	14.82	14.07	142	30119	316625	110242413
Interstitial lung disease	14.76	14.07	10	30251	139324	110419714
Treatment failure	14.60	14.07	34	30227	277200	110281838
Freezing phenomenon	14.52	14.07	9	30252	2600	110556438
Vulvovaginal inflammation	14.47	14.07	6	30255	743	110558295
Arthralgia	14.45	14.07	140	30121	779492	109779546
Arthrodesis	14.18	14.07	9	30252	2709	110556329
Vaginal infection	14.13	14.07	13	30248	6791	110552247
Body surface area increased	14.08	14.07	4	30257	157	110558881

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A01AB18	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	D01AC01	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF02	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:35718	antifungal agent
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:75835	anti-anaemic agent
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D000935	Antifungal Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D065088	Steroid Synthesis Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
CHEBI has role	CHEBI:78298	environmental contaminant
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

A01AB Antiinfectives and antiseptics for local oral treatment 22 drugs

amphotericin B benzoxonium chloride cetylpyridinium chlorhexidine chlortetracycline domiphen doxycycline hexetidine hydrogen peroxide mepartricin metronidazole miconazole show all 22 →

D01AC Imidazole and triazole derivatives 20 drugs

bifonazole chlormidazole eberconazole econazole efinaconazole fenticonazole fluconazole flutrimazole isoconazole ketoconazole lanoconazole luliconazole show all 20 →

G01AF Imidazole derivatives 16 drugs

azanidazole butoconazole econazole fenticonazole flutrimazole isoconazole ketoconazole metronidazole miconazole omoconazole ornidazole oxiconazole show all 16 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Candidiasis of skin	indication	49883006
Pityriasis versicolor	indication	56454009	DOID:9060
Candidal vulvovaginitis	indication	72605008	DOID:2272
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Diaper rash	indication	91487003
Tinea cruris	indication	399029005
Prevention of Oropharyngeal Candidiasis	indication
Oropharyngeal Candidiasis	indication
Paronychia	off-label use	71906005	DOID:13117
Telangiectasia disorder	contraindication	247479008
Abdominal pain - cause unknown	contraindication	314212008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Fungal infections caused by Microsporum canis	Indication
Cats	Fungal infections caused by Trichophyton mentagrophytes	Indication
Cats	Otitis externa caused by yeast, Malassezia pachydermatis	Indication
Dogs	Fungal infections caused by Microsporum canis	Indication
Dogs	Fungal infections caused by Trichophyton mentagrophytes	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Veltrim 1% Dermatologic Cream	Elanco US Inc.	1
Otomax	Intervet Inc.	3
Mometamax Otic Suspension	Intervet Inc.	3
Tri-Otic Ointment	Med-Pharmex Inc.	3
Vetro-Max	Fougera Pharmaceuticals Inc.	3
GBC Ointment	Cronus Pharma Specialities India Private Limited	3
Mometavet	Med-Pharmex Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.4	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1%	CLOTIC	CARWIN PHARM ASSOC	N217628	Sept. 26, 2025	RX	SOLUTION/DROPS	OTIC	12246006	May 26, 2042	TREATMENT OF FUNGAL OTIC INFECTION (FUNGAL OTITIS EXTERNA, OTOMYCOSIS) DUE TO ASPERGILLUS SPECIES AND CANDIDA SPECIES

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1%	CLOTIC	CARWIN PHARM ASSOC	N217628	Sept. 26, 2025	RX	SOLUTION/DROPS	OTIC	Sept. 26, 2028	NEW PRODUCT
1%	CLOTIC	CARWIN PHARM ASSOC	N217628	Sept. 26, 2025	RX	SOLUTION/DROPS	OTIC	Sept. 26, 2032	TREATMENT OF FUNGAL OTITIS EXTERNA (OTOMYCOSIS) DUE TO ASPERGILLUS SPECIES AND CANDIDA SPECIES IN PATIENTS 18 YEARS OF AGE AND OLDER
1%	CLOTIC	CARWIN PHARM ASSOC	N217628	Sept. 26, 2025	RX	SOLUTION/DROPS	OTIC	Sept. 26, 2033	GENERATING ANTIBIOTIC INCENTIVES NOW
1%	CLOTIC	CARWIN PHARM ASSOC	N217628	Sept. 26, 2025	RX	SOLUTION/DROPS	OTIC	Sept. 26, 2037	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	4.38	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN	ANTAGONIST	IC50	6.16	IUPHAR
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.14	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.35	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.39	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.15	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.35	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.52	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	7.70	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.17	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.51	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.10	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.00	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.50	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.13	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.12	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.24	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.43	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.05	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.47	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	5.78	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.68	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	5.79	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.83	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.27	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.35	DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	5.11	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.57	DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN		IC50	7.15	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	5.57	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.16	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	4.52	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.13	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.60	DRUG MATRIX
Calcium-activated potassium channel subunit alpha-1	Ion channel	Q12791	KCMA1_HUMAN	BLOCKER	IC50	5.52	IUPHAR
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.76	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	4.71	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	7.80	DRUG MATRIX
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	4.65	DRUG MATRIX
Aromatase	Enzyme	P11511	CP19A_HUMAN		IC50	8.74	CHEMBL
Cysteinyl leukotriene receptor 1	GPCR	Q9Y271	CLTR1_HUMAN		Ki	4.78	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.16	DRUG MATRIX
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		IC50	5.60	CHEMBL
Substance-P receptor	GPCR	P25103	NK1R_HUMAN		Ki	5.06	DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN		IC50	7.09	WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3	Ion channel	P22001	KCNA3_HUMAN		IC50	5.22	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	7.80	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	4.50	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	4.18	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	7.85	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.49	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	6.89	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.92	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.47	DRUG MATRIX
Transient receptor potential cation channel subfamily M member 2	Ion channel	O94759	TRPM2_HUMAN		IC50	5.52	CHEMBL
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN		IC50	5.80	CHEMBL
C-X-C chemokine receptor type 1	GPCR	P25024	CXCR1_HUMAN		IC50	5.70	CHEMBL
Transient receptor potential cation channel subfamily M member 8	Ion channel	Q7Z2W7	TRPM8_HUMAN		IC50	5.10	CHEMBL
Transitional endoplasmic reticulum ATPase	Enzyme	P55072	TERA_HUMAN		IC50	5.85	CHEMBL
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.46	CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	Enzyme	Q9UNU6	CP8B1_HUMAN		IC50	6.10	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.19	DRUG MATRIX
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR			CHEMBL	CHEMBL
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.11	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	4.91	DRUG MATRIX
Cysteinyl leukotriene receptor 1	GPCR		CLTR1_CAVPO		Ki	4.78	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.58	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	4.75	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_MYCTU		Kd	6.70	CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	5.32	CHEMBL
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	6.99	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	5.23	CHEMBL
Mycocyclosin synthase	Enzyme		CP121_MYCTU		Kd	7.14	CHEMBL
Putative cytochrome P450 130	Enzyme		CP130_MYCTU		Kd	4.88	CHEMBL
Alpha-chymotrypsin	Enzyme		CTRA_BOVIN		IC50	4.07	CHEMBL
Indoleamine 2,3-dioxygenase 1	Enzyme		I23O1_MOUSE		IC50	4.29	CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Enzyme		AT2A1_RABIT		Ki	4.46	CHEMBL

External reference:

ID	Source
4018265	VUID
N0000146595	NUI
D00282	KEGG_DRUG
202859	RXNORM
C0009074	UMLSCUI
CHEBI:3764	CHEBI
CL6	PDB_CHEM_ID
CHEMBL104	ChEMBL_ID
DB00257	DRUGBANK_ID
D003022	MESH_DESCRIPTOR_UI
2812	PUBCHEM_CID
2330	IUPHAR_LIGAND_ID
2912	INN_ID
G07GZ97H65	UNII
1284	MMSL
4482	MMSL
d01236	MMSL
002916	NDDF
387325003	SNOMEDCT_US
5797005	SNOMEDCT_US
4018265	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0133	CREAM	10 mg	TOPICAL	ANDA	20 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0258	CREAM	10 mg	TOPICAL	ANDA	27 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
WALGREENS CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0363-1299	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
Walgreens Clotrimazole 3	HUMAN OTC DRUG LABEL	1	0363-2062	CREAM	2 g	VAGINAL	NDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-2105	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Ringworm	HUMAN OTC DRUG LABEL	1	0363-2107	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Walgreens Jock Itch	HUMAN OTC DRUG LABEL	1	0363-2109	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-3492	LIQUID	1 mg	TOPICAL	OTC monograph final	8 sections
Walgreens Clotrimazole Antifungal	HUMAN OTC DRUG LABEL	1	0363-7412	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0536-1181	SOLUTION	1 g	TOPICAL	OTC Monograph Drug	13 sections
Rugby Clotrimazole Antifungal Cream	HUMAN OTC DRUG LABEL	1	0536-1265	CREAM	1 g	TOPICAL	OTC Monograph Drug	12 sections
RUGBY ANTIFUNGAL CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0536-1272	CREAM	0.01 g	TOPICAL	OTC Monograph Drug	14 sections
CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0536-1443	SOLUTION	1 g	TOPICAL	OTC Monograph Drug	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0107	LOZENGE	10 mg	ORAL	ANDA	18 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	10135-671	SOLUTION	1 g	TOPICAL	OTC Monograph Drug	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	10135-671	SOLUTION	1 g	TOPICAL	OTC Monograph Drug	14 sections
Lotrimin	HUMAN OTC DRUG LABEL	1	11523-0963	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
LotriminAntifungal	HUMAN OTC DRUG LABEL	1	11523-1125	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Lotrimin	HUMAN OTC DRUG LABEL	1	11523-6549	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Dr Sheffield Athletes Foot	HUMAN OTC DRUG LABEL	1	11527-071	CREAM	10 mg	TOPICAL	OTC Monograph Drug	11 sections
Jock Itch	HUMAN OTC DRUG LABEL	1	11673-062	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Target Jock Itch	HUMAN OTC DRUG LABEL	1	11673-893	CREAM	10 mg	TOPICAL	OTC Monograph Drug	11 sections
UpandUp Clotrimazole	HUMAN OTC DRUG LABEL	1	11673-910	CREAM	10 mg	TOPICAL	OTC Monograph Drug	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	11822-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	11822-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections